FDA Approves Weekly Insulin Awiqli for Pediatric T2D

FDA has approved Awiqli (insulin icodec-abae) for children 10 years and older with type 2 diabetes, Novo Nordisk said 23 October 2026 — the first once-weekly basal insulin cleared for a pediatric population. The approval extends a drug FDA first cleared for adults in March 2026, and it leans on that adult record rather than a new pediatric efficacy trial.

An adult insulin, extended down

Insulin icodec is a basal insulin analog engineered for a week-long duration of action — modifications that slow its clearance and strengthen its albumin binding let a single injection cover seven days, instead of the once- or twice-daily dosing that conventional basal insulins require. FDA approved it for adults with type 2 diabetes under the brand name Awiqli in March 2026, built on Novo Nordisk's ONWARDS trial program. The 23 October action does not approve a new drug or a new indication; it extends the existing adult label to patients as young as 10.

The evidence behind the extension

FDA did not require a new randomized efficacy trial in children before approving the pediatric extension. Instead, the agency accepted the adult efficacy and safety record already on file, paired with a single-dose pharmacokinetic study conducted specifically in patients 10 to under 18 years old, to confirm the drug behaves predictably in a younger body before extrapolating the adult findings down. That is a narrower evidentiary bar than a dedicated pediatric efficacy trial, and the label says so directly: safety and efficacy in children under 10 have not been established, because neither the adult data nor the adolescent PK study extend to that younger population.

What the label covers, and what it doesn't

• Indication: adjunct to diet and exercise to improve glycemic control in patients 10 years and older with type 2 diabetes.
• Evidentiary basis: adult Phase 3 data (ONWARDS program) plus a single-dose pharmacokinetic study in ages 10 to under 18 — no new pediatric efficacy trial.
• Not established: safety and efficacy in children under 10 years of age.
• Standard insulin risks: hypoglycemia, serious allergic reactions, injection-site reactions, lipodystrophy and weight gain — the same warnings that apply across basal insulins, not findings specific to the pediatric extension.

Why once-weekly matters for adolescents

Daily basal-insulin injections are a well-documented adherence problem in adolescents with type 2 diabetes — a population juggling school, sports and a condition many would rather not think about every day. A once-weekly regimen cuts the required number of injections from roughly 365 a year to 52, which is the practical case for extending the drug down rather than relying only on daily options. FDA's approval does not itself specify a pediatric starting dose in the public announcements reviewed for this story; prescribers and pharmacists should confirm current dosing and titration guidance in Awiqli's full prescribing information before initiating a pediatric patient, rather than carrying over an adult starting dose by assumption.

Frequently asked questions

What did FDA approve?

Awiqli (insulin icodec-abae), Novo Nordisk's once-weekly basal insulin, for children 10 years and older with type 2 diabetes, as an adjunct to diet and exercise. The approval was announced 23 October 2026. It is the first once-weekly basal insulin available to this pediatric age group.

What evidence supports the pediatric approval?

FDA relied on Awiqli's existing adult efficacy and safety record, built through Novo Nordisk's ONWARDS clinical program, plus a single-dose pharmacokinetic study conducted in patients 10 to under 18 years old. No new pediatric efficacy trial was required.

Is this a new drug?

No. Awiqli was already approved for adults with type 2 diabetes, roughly seven months earlier, in March 2026. This action extends an existing adult label down to a pediatric population rather than approving a new molecule or a new indication.

What is not established?

Safety and efficacy in children under 10 years of age have not been established. The label carries the standard warnings that apply to basal insulins generally: hypoglycemia, serious allergic reactions, injection-site reactions, lipodystrophy and weight gain.